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1602Dynamics of Cytomegalovirus (CMV) Plasma DNAemia
in Initial and Recurrent Episodes of Active CMV
Infection in the Allogeneic Stem Cell Transplantation
Setting: Implications for Designing Preemptive
Antiviral Therapy Strategies
Beatriz Mu~noz-Cobo,1 Carlos Solano,2,3 Elisa Costa,1 Dayana Bravo,1 Marıa Angeles Clari,1
Isabel Benet,2,3 Marıa Jose Remigia,2 Juan Montoro,2 David Navarro1,4Preemptive antiviral therapy strategies for active cytomegalovirus (CMV) infection occurring in allogeneic
stem cell transplant recipients should be optimized to avoid overtreatment. The current study was aimed
at determining whether the analysis of the kinetics of CMV DNA load in plasma may provide useful informa-
tion for the therapeutic management of active CMV infection in this setting. A total of 59 consecutive patients
were included in the study, of which 40 (67.8%) developed 1 (n 5 21) or more (n 5 19) episodes of
CMV DNAemia. The need for antiviral therapy for initial or secondary episodes of CMV DNAemia could
not be predicted on the basis of the CMV DNA load value in the first plasma testing positive by polymerase
chain reaction (PCR). In contrast, in the absence of antiviral therapy, an increase of $3-fold between the
baseline CMV DNA load and that measured a median of 6 days later discriminated between initial episodes
eventually requiring antiviral treatment and those resolving spontaneously (sensitivity, 76.4%; specificity,
89.4%; positive predictive value, 86.6%; negative predictive value, 80.9%). This criterion was not useful for
identifying recurrent episodes of CMV DNAemia that required antiviral therapy. The CMV doubling time
and CMVDNA loads at the time of the first positive PCR and at initiation of preemptive therapy did not differ
significantly between episodes that responded immediately to antiviral therapy from those showing a delayed
response. The analysis of the dynamics of CMV DNA load in plasma in the absence of antiviral therapy
allowed early recognition of episodes of CMV DNAemia that eventually needed to be treated, but did
not permit prediction of the kinetics of CMV DNA clearance in response to antiviral therapy.
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6/j.bbmt.2011.08.014cell transplantation (allo-SCT) [1]. Preemptive anti-
viral therapy, consisting of the administration of anti-
virals upon detection of CMV replication in the blood
compartment, has been adopted by most transplant
centers as the first-choice strategy for the prevention
of CMV end-organ disease [2]. In recent years, most
laboratories have switched from the pp65 antigenemia
assay to quantitative real-time polymerase chain
reaction (PCR) methods for the surveillance of active
CMV infection and guidance of preemptive antiviral
therapy. In this setting, antiviral treatment is usually
initiated when the CMV DNAemia level reaches
a certain predetermined threshold (ranging from
1000 to 10,000 copies/mL in whole blood, or from
100 to 10,000 copies/mL of plasma) [2,3]. At some
centers, the CMV DNA load cutoff triggering the
initiation of antiviral therapy is stratified according
to the individual risk of patients for developing
Table 1. Demographic and Clinical Data of the Patients
Parameter No. of Patients (%)
Patients 59
Median age, years (range) 49 (16-71)
Sex, no. male patients/no. female patients 39/20
Underlying disease
Acute myeloid leukemia 24 (40.6)
Non-Hodgkin’s lymphoma 16 (27.1)
Acute lymphocytic leukaemia 6 (10.1)
Chronic lymphocytic leukaemia 4 (6.7)
Multiple myeloma 2 (3.3)
Myelodysplastic syndrome 2 (3.3)
Hodgkin’s lymphoma 2 (3.3)
Myeloproliferative syndrome 1 (1.6)
Chronic myeloid leukaemia 1 (1.6)
Plasma cell disorders 1 (1.6)
CMV-serostatus
D+/R+ 28 (47.4)
D2/R+ 22 (37.2)
D+/R2 5 (8.5)
D2/R2 4 (6.7)
Donor type
HLA-identical sibling 28 (47.4)
Matched unrelated 20 (33.9)
Mismatched related 2 (3.4)
Mismatched unrelated 9 (15.3)
Conditioning regimen
Nonmyeloablative 35 (59.3)
Melphalan/Fludarabine 23 (38.9)
Busulfan/Fludarabine 7 (11.8)
Melphalan/Fludarabine/Rituximab 5 (8.4)
Myeloablative 24 (40.7)
Busulfan/Cyclophosphamide 11 (18.6)
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occurs [3]. Alternatively, preemptive therapy may be
initiated upon a documented increase in CMVDNAe-
mia between 2 consecutive determinations [3-5].
Although preemptive antiviral therapy regimens have
been shown to effectively prevent the occurrence of
CMV end-organ disease, they probably result in over-
treatment [6,7].
The analysis of the dynamics of CMV replication
during active CMV infection in allo-SCT recipients
has been shown to be useful for predicting the risk of
CMV end-organ disease and nonrelapse mortality
[8-11], the likelihood of the occurrence of recurrent
episodes of active CMV infection, and the kinetics of
response to antiviral therapy [12,13]. Nevertheless,
no practical therapeutic intervention measures have
been derived from these studies. The current study
was aimed at determining whether knowledge
regarding the kinetics of CMV DNA load in plasma
may provide useful information for the therapeutic
management of active CMV infection in allo-SCT
recipients. In addition, the effects of pretransplant
and clinical factors on the kinetic pattern of CMV
plasmaDNAemia clearance in initial episodes of active
CMV infection and on the incidence of recurrent
episodes in this clinical setting were investigated.Busulfan/Fludarabine/
Thiotepa/Antytimoglobulin 10 (16.9)
Busulfan/Cyclophosphamide/Antytimoglobulin 2 (3.2)
Fludarabine/Busulfan/Antytimoglobulin 1 (1.6)
Stem cell source
Peripheral blood 50 (84.7)
Umbilical cord blood 9 (15.3)
GVHD prophylaxis
Cyclosporin A/Methotrexate 33 (55.9)
Cyclosporin A/mycophenolate
mofetil 9 (15.3)
Rapamycin + Tacrolimus 10 (16.9)
Cyclosporine A/Prednisone 3 (5.1)
Others 4 (6.7)
Acute GVHD
Grades 0-I 36 (61.1)
Grades II-IV 23 (38.9)
D indicates donor; R, recipient; +, CMV seropositive;2, CMV seroneg-PATIENTS AND METHODS
Patients
A total of 59 consecutive patients undergoing non-
manipulated T cell replete allo-SCT between January
2009 and March 2011 at the Hospital Clınico Univer-
sitario of Valencia were included in the study. Relevant
clinical and demographic data of the patients are sum-
marized in Table 1. The study was approved by the
Ethics Committee, and all patients gave their informed
consent to participate in the study.ative.
Age is given as median (range).Management of Active CMV Infection
Virologic monitoring of CMV infection was per-
formed using the Abbott CMV PCR Kit (produced
by Qiagen GmbH, Hilde, Germany for Abbott Diag-
nostics, Des Plaines, IL) [4], on the m2000RT system
(Abbott Molecular, Des Plaines, IL). In our experi-
ence, this assay is able to reliably quantify CMV
DNA loads .10 copies/mL [14]. Nucleic acid extrac-
tion was performed with the Abbott mSample prepara-
tion system DNA Kit on the m24 SP instrument
(Abbott Diagnostics) using 500 mL of plasma. Viro-
logic monitoring was performed weekly within the first
120 days following transplantation and at each sched-
uled patient visit thereafter. During episodes of active
CMV infection, virologic monitoring was scheduled tobe performed twice a week, although this was not done
for all patients.
Patients with active CMV infection were preemp-
tively treated with oral valganciclovir (900 mg/12 h),
i.v. ganciclovir (5 mg/kg/12 h) or foscarnet (i.v.
60 mg/kg/12 h) upon detection of .500 CMV DNA
copies/mL in the plasma. Antiviral therapy was discon-
tinued after 2 consecutive negative PCR results
obtained 3 to 7 days apart. All patients with antibodies
against herpes simplex virus received acyclovir prophy-
laxis as follows: recipients of unrelated grafts
were treated with i.v. acyclovir (750 mg/8 h) when
either the patient, the donor or both were
1604 Biol Blood Marrow Transplant 17:1602-1611, 2011B. Mu~noz-Cobo et al.CMV-seropositive; recipients of related grafts and
CMV-seronegative patients receiving an unrelated
graft from a CMV-seronegative donor were treated
with oral acyclovir (800 mg/12 h). Acyclovir was ad-
ministered until stable hematopoietic cell engraftment
was achieved, usually around day 130.Definitions
Active CMV infection was diagnosed upon detec-
tion of CMV DNA (any level) in 1 or more plasma
specimens. Episodes of active CMV infection with
only 1 specimen testing positive by PCR were consid-
ered true episodes if a different aliquot of plasma also
tested positive. For data analysis, the commencement
and end of a given episode of active viral infection
were defined by the first positive (any level of plasma
viral load) and first negative results, respectively.
Only increases in CMVDNA loads$3 times the base-
line levels were considered true increases, as these were
above the intraassay variability of the PCR test
(approximately, 0.2 log10 for low CMV DNA values)
[3]. Recurrent episodes of active CMV infection were
those that occurred at least 15 days after clearance (first
negative PCR) of the preceding episode. CMV end-
organ disease was diagnosed and treated as previously
reported [15].Analyses of the Kinetics of CMV Plasma
DNAemia
To determine the rate of virus replication, the viral
doubling time (dt) of CMV was estimated considering
for analysis the first 2 PCR positive results in the
absence of antiviral treatment [16]. The dt was given
by dt 5 (t2 2 t1)  log(2)/log(q2/q1), with q1 and t1
being the CMV DNA load (copies/mL) at the time of
the first positive PCR (in days), respectively, and q2
and t2 the CMV DNA load at the time of the second
positive PCR, respectively. This formula assumes
a constant growth rate, which occurs in the early phase
of virus replication. CMV dt calculations were per-
formed only for episodes in which the increase in
CMVDNA load between the first and the second pos-
itive PCR determinations was$3-fold. The kinetics of
CMV DNA load clearance followed a logarithmic
decay curve in most treated episodes but only in a few
self-resolving episodes (see below), expressed by the
equation yt 5 y0e
2kt, where y0 is the initial CMV
DNA load, t is time from initiation of antiviral therapy
(for self-resolving episodes, t is the duration of the
episode), and k is the decay constant [12,17,18]. A
nominal value of 9 copies/mL was arbitrarily ascribed
for plasma specimens with undetectable CMV DNA
load, on the basis of the actual limit of detection of
the assay. CMVDNA load half-life was then calculated
using the equation ln2/k.Statistical Analysis
The data were analyzed with the aid of the statisti-
cal package SPSS version 17.0 (SPSS, North Chicago,
IL).Comparisonswere carried out using the chi-square
test for categoric variables and the nonparametric
Mann-Whitney U-test or the Wilcoxon signed-rank
test for unpaired or paired continuous data, respec-
tively. Two-sided exact P values are reported. A
P value\.05 was considered statistically significant.RESULTS
Incidence of CMV Plasma DNAemia during the
Study Period
Forty of 59 patients (67.8%) developed 1 (n 5 21)
or more (n 5 19) episodes of CMV DNAemia during
the study period. Three of the latter 19 patients expe-
rienced more than 2 episodes (in all, 63 episodes were
detected). The patients were followed up for a median
of 220 days (range: 10-375 days).
Virologic Features of Initial Episodes of CMV
Plasma DNAemia
Initial episodes of CMV plasma DNAemia were
detected at a median of 30 days (range: 1-90 days) after
transplantation. Twenty-three out of the 40 episodes
(57%) resolved spontaneously. Of these, 19 had .1
specimen testing positive by PCR. Twelve of the
remaining 17 episodes cleared following instauration
of antiviral therapy. The median time to the first
CMVDNA positive result was not significantly differ-
ent for self-resolving or for treated episodes (P5 .930).
The CMV DNA load in plasma rapidly declined after
implementation of antiviral therapy in 5 episodes
(type A episodes), whereas in 12 episodes, CMV
DNA load increased within the next 2 to 3 weeks
following the instauration of antiviral therapy, and
then progressively declined (type B episodes). Five
treated episodes (type B) were still active at the time
of the patient’s death. As shown in Table 2, the dura-
tion of CMV DNAemia was significantly shorter for
self-resolving episodes than for treated episodes
(P 5 .001), irrespective of whether the latter were
type A (P 5 .022) or type B (P 5 .001) episodes. The
duration of type B episodes was longer than that of
type A episodes, although the difference did not reach
statistical significance (P 5 .432).
In most of self-resolving episodes (15 of 19 epi-
sodes with .1 positive PCR result), either fluctuating
or rather stable levels of CMV DNA loads (mean dif-
ference between samples\0.2 log10 copies/mL) were
observed until resolution. In the remaining 4 episodes,
CMV DNA load decline did follow an exponential
function (Figure 1). The CMV DNA load decay rate
(k) in these episodes was lower than for treated
Table 2. Virologic Features of Initial Episodes of Cytomegalovirus (CMV) Plasma DNAemia
Type of Episode
(No. of Episodes)
Initial VL
(Copies/mL)
VL at Treatment
(Copies/mL)
Peak VL
(Copies/mL)
Duration
(Days)
Virus Doubling
Time (Days) Kdecline/Day
21 Half-Life (Days)
Self-resolving (23) 28 (20-135) NA 40 (25-308) 16 (3-48) NA 0.13 (0.09-0.27) 5.57 (2.52-7.43)
Treated (17) 70 (25-216) 1,216 (523-15,244) 3,872 (676-66,329) 40.5 (18-130) 2.18 (1.04-8.76) 0.35 (0.06-0.65) 1.90 (1.06-11.50)
Treated Type A* (5) 63 (25-133) 1,455 (676-1,739) 1,455 (676-1739) 40 (21-68) 4.45 (1.20-8.76) 0.37 (0.18-0.37) 1.87 (1.83-3.85)
Treated Type B† (12) 79 (28-216) 939 (523-15,244) 9,907 (918-66,329) 44 (18-130) 2.01 (1.04-3.10) 0.14 (0.06-0.65) 4.77 (1.06-11.50)
VL indicates CMV DNA load; NA, not applicable.
Figures are given as median numbers (range).
*Immediate response to antiviral therapy.
†Delayed response to antiviral therapy.
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reached (P 5 .297). Accordingly, the median half-life
of CMV DNA load was shorter in treated episodes
than in self-resolving episodes (P5 .304). The median
value of k was higher for type A than for type
B episodes (P 5 .422). Thus, the median half-life of
CMV DNA load was shorter in type A than in type
B episodes (P 5 .287).Analysis of Early Kinetics of CMV DNAemia for
Predicting the Virologic Outcome of Initial
Episodes of Active CMV Infection
The median initial CMV DNA load (first positive
PCR) was significantly lower (P 5 .001) in self-
resolving episodes than in those that were eventually
treated. Type A and type B episodes had comparable
initial CMV DNA viral loads (P 5 .62). Despite theDays
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Figure 1. Initial episodes of active CMV infection that resolved spontaneou
exponential decay function. Black circles are data points. The line of best fit isabove findings, a cutoff value for the initial CMV
DNA load reliably predicting the subsequent kinetics
of CMV DNAemia could not be established, because
of a high degree of overlap.
We next sought to determine whether the compar-
ison of CMV DNA loads measured at baseline (initial
viral load) and shortly thereafter (second positive
PCR), a median of 6 days (range: 4-8 days) after the
first positive PCR, would allow for discriminating
between episodes eventually requiring antiviral treat-
ment from those that would resolve without the
need of antiviral therapy. No significant variation
(\3-fold) in the CMV DNA load between measure-
ments was observed in 17 of 19 self-resolving episodes
(see Figure 2A and B). A significant increase ($3-fold)
in CMVDNA load was found in 3 of 5 type A episodes
and in 10 of 12 type B episodes (Figure 2C). Thus, the
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Figure 2. (A) Kinetics of CMV plasma DNAemia in initial episodes of active CMV infection that resolved spontaneously. A $3-fold increase of
CMVDNA load between the values in the first and second PCR positive specimens was documented in only 2 episodes (B). Early kinetics of CMV plasma
DNAemia in initial episodes of active CMV infection that were eventually treated preemptively with antivirals (n5 17), before initiation of therapy (C). In
5 of these episodes (white triangles) CMV DNA load rapidly decreased following instauration of antiviral therapy in 5 episodes; in the remaining
12 episodes, a delayed response to therapy was observed (black diamonds). Day 0 represents the day of the first positive PCR result.
1606 Biol Blood Marrow Transplant 17:1602-1611, 2011B. Mu~noz-Cobo et al.negative predictive value for this criterion to identify
episodes that required therapeutic intervention were
76.4%, 89.4%, 86.6%, and 80.9%, respectively.
As shown in Table 2, the doubling times for CMV
in the 2 self-resolving episodes inwhich a significant in-
crease in CMV DNA load was documented (2.77 and
3.18) were slightly lower than for treated episodes (me-
dian, 2.18; range: 1.04-8.76). The CMV doubling time
was higher for typeA than for typeB episodes, although
the difference did not reach statistical significance (P5
.160). In addition, the median CMV DNA load at the
time of initiation of preemptive therapy was not signif-
icantly different between type A and type B episodes
(P 5 .743).
Effects of Pretransplant and Clinical Factors on
the Kinetic Pattern of First Episodes of CMV
DNAemia
As shown in Table 3, nonsignificant tendencies to
experience more frequent episodes of CMVDNAemia
requiring antiviral therapy were observed in patients
receiving cord blood orHLA-mismatched grafts in pa-
tients who had undergone myeloablative conditioning
or in those who were treated with MMF or prednisone
as a part of the graft-vs-host disease (GVHD) prophy-
laxis regimen. CMV D1/R1 allo-SCT recipients
developed more frequently self-resolving episodes
than D2/R1 or D1/R2 patients, although the differ-ence did not reach statistical significance. Likewise,
a trend toward a higher incidence of episodes requiring
antiviral therapy was observed in patients with a prior
diagnosis of acute grade II-IV GVHD. Interestingly,
episodes requiring antiviral therapy for resolution
appeared to occur at a lower frequency in patients
treated with rapamycin as a part of theGVHDprophy-
laxis regimen than in those treated with other combi-
nations of immunosuppressive drugs.
Virologic Features of Recurrent Episodes of
CMV DNAemia
Twelve of 23 patients (52.1%) experiencing an ini-
tial self-resolving episode of active CMV infection
developed a recurrent episode of CMV DNAemia
within the first year after transplantation. All of these
12 episodes resolved without therapeutic intervention
(9 had .1 positive PCR result). The incidence of
recurrent episodes of CMV DNAemia in patients
who had experienced a treated episode (7 of 17 pa-
tients, 42%) was comparable to the incidence in
patients with prior self-resolving episodes (P 5 .905).
Nevertheless, 3 of these 7 secondary episodes required
antiviral treatment (2 were type B and 1 was type A
episodes). In addition, recurrent episodes of CMV
DNAemia occurred with equal frequencies following
type A and type B episodes (P 5 1.0). The virologic
features of recurrent episodes of CMV DNAemia are
Table 4. Virologic Features of Recurrent Episodes of CMV
Plasma DNAemia
Virologic Parameter
Type of Episode
P Value*Self-Resolving Treated
Initial VL (copies/mL) 25 (20-63) 35 (28-161) .054
Peak VL (copies/mL) 43 (22-477) 1,012 (5674-1395) .002
Duration (days) 19 (6-67) 34 (26-35) .295
Day of first + PCR 96 (54-260) 160 (96-180) .421
VL indicates CMV DNA load.
Figures are given as median numbers (range).
*As determined by the Mann-Whitney U-test; A P value #.05 was con-
sidered statistically significant.
Table 3. Effects of Pretransplant and Clinical Factors on the
Occurrence of Self-Resolving or Treated Initial Episodes of
Cytomegalovirus (CMV) DNAemia
Factor
No. of Patients with Active
CMV Infection (%)
P Value*Total Self-Resolving Treated
CMV-serostatus
D+/R+ 21 13 (61.9) 8 (38.1)
D2/R+ 16 9 (56.2) 7 (43.8)
D+/R2 3 1 (25.0) 2 (75.0) .623
Type of donor
and HLA match
Related/matched 17 10 (58.8) 7 (41.2)
Related/mismatched 2 0 (0.0) 2 (100.0)
Unrelated/matched 13 9 (69.2) 4 (30.8)
Unrelated/mismatched 8 4 (50.0) 4 (50.0) .388
Stem cells source
Peripheral blood 32 19 (59.3) 13 (40.7)
Cord blood 8 4 (50.0) 4 (50.0) .702
Conditioning
Myeloablative 19 10 (52.6) 9 (47.4)
Nonmyeloablative 21 13 (61.9) 8 (39.1) .750
GVHD prophylaxis
CSA + MTX 20 14 (65.0) 6 (35.0)
CSA + MMF 9 4 (44.4) 5 (55.6)
Rapamycin/Tacrolimus 7 5 (71.4) 2 (29.6)
CSA + PDN 2 0 (0.0) 2 (100.0) .123
Acute GVHD†
Grades 0-I 25 14 (56.0) 11 (44.0)
Grades II-IV 10 5 (50.0) 5 (50.0) 1.0
D indicates donor; R, recipient; CSA, cyclosporine A; MTX, methotrex-
ate; MMF, mycophenolate mofetil; PDN, prednisone.
*Frequency comparisons were carried out using the chi-square test
(Fisher’s exact test). A P value#.05was considered statistically significant.
†Only those cases in which acute GVHD occurred before detection of
CMV DNAemia were considered for analysis.
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episodes was longer than that of self-resolving
episodes, although statistical significance was not
reached. As for first episodes, the initial CMV DNA
load in recurrent episodes was significantly higher in
self-resolving episodes than in treated episodes,
although again, a high degree of overlap was observed.
Nevertheless, in contrast to what was observed in
initial episodes, variation in CMV DNA load between
baseline levels and those measured in the second pos-
itive PCR did not allow for discrimination betweenDays
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Figure 3. (A) Kinetics of CMV plasma DNAemia in recurrent episodes of a
plasma DNAemia in initial episodes of active CMV infection that required pree
the day of the first positive PCR result.episodes resolving spontaneously (Figure 3A) and
those requiring antiviral therapy (Figure 3B). In fact,
significant variations between measurements were
observed in none out of 9 self-resolving episodes
with more than 1 positive PCR result and in 1 of 3 ep-
isodes eventually treated (Figure 3B). The CMVDNA
load decay rate in these episodes was a median of
0.24 day21 (range: 0.16-0.59 day21), which corre-
sponded to a median half-life of 2.85 days (range:
1.17-4.10 days). The kinetics of CMV DNAemia
clearance for secondary episodes that resolved sponta-
neously did not follow an exponential decay function
(not shown).
Effects of Pretransplant and Clinical Factors
on the Incidence of Recurrent Episodes of CMV
DNAemia
A trend toward a more frequent occurrence of
recurrent episodes of CMV DNAemia was observed
in CMV D2/R1 patients, and in the setting of unre-
lated/mismatched and umbilical cord blood allo-SCT.
The differences, however, did not reach statistical
significance (Table 5).
Kinetics of CMV Plasma DNAemia in Patients
with CMV End-Organ Disease
Two patients developed CMV end-organ disease
(enteritis) within the first 100 days after transplantation.
Both received unrelated/HLA-matched peripheralDays
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mptive antiviral therapy before initiation of treatment. Day 0 represents
Table 5. Effects of Pretransplant and Clinical Factors on the
Incidence of Recurrent Episodes of Cytomegalovirus (CMV)
DNAemia within the Study Period
Factor
Recurrent Episode of CMV
DNAemia No. of Patients (%)
P Value*Yes No
CMV-serostatus
D+/R+ 9 (42.8) 12 (57.2)
D2/R+ 10 (62.5) 6 (37.5)
D+/R2 0 (0) 3 (100) .111
Type of donor
and HLA match
Related/matched 8 (47.0) 9 (53.0)
Related/mismatched 0 (0) 2 (100)
Unrelated/matched 6 (46.1) 7 (53.9)
Unrelated/mismatched 5 (62.5) 3 (37.5) .655
Stem cells source
Peripheral blood 14 (43.7) 18 (56.3)
Cord blood 5 (62.5) 3 (37.5) .442
Conditioning
Myeloablative 10 (52.6) 9 (47.4)
Nonmyeloablative 9 (42.8) 12 (57.2) .752
GVHD prophylaxis
CSA + MTX 10 (50.0) 10 (50.0)
CSA + MMF 5 (55.5) 4 (45.5)
Rapamycin/Tacrolimus 4 (57.1) 3 (42.9)
CSA + PDN 0 (0) 2 (100) .123
Acute GVHD†
Grades 0-I 14 (56.0) 11 (44.0)
Grades II-IV 7 (46.6) 8 (53.4) .504
D indicates donor; R, recipient; CSA, cyclosporine A; MTX, Methotrex-
ate; MMF, mycophenolate mofetil; PDN, prednisone.
*Frequency comparisons were carried out using the chi-square test
(Fisher’s exact test). A P value#.05 was considered statistically significant.
†Only those cases in which acute GVHD occurred before detection of
CMV DNAemia were considered for analysis.
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loablative regimen (fludarabine plus melphalan) and
were treated with cyclosporine A and methotrexate for
prophylaxis of GVHD. CMV-serostatus of donors
and recipients were D1/R1 in 1 case and D2/R1 in
the other. Neither of these patients developed acute
GVHD (aGVHD). Both patients had low initial
CMVDNAemia levels (91 and 28 copies/mL). A signif-
icant increase in CMV DNA load before initiation of
antiviral therapy was observed in 1 of these episodes
(dt 5 2.5 days). Both episodes (type B) were treated
with i.v. ganciclovir and had a duration of 102 and
87 days, respectively. The peak of CMV DNAemia
was reached at days 121 (66,329 copies/mL) and
130 (35,431 copies/mL), respectively, after the first
positivePCRresult.Bothpatientsdevelopedarecurrent
episode of CMV DNAemia.DISCUSSION
In the current study, we took advantage of a highly
sensitive real-time PCR and a relatively conservative
strategy for initiation of preemptive antiviral therapy
(.500CMVDNA copies/mL in plasma) to investigatewhether the analysis of the kinetics of CMVDNAemia
may yield useful information for the therapeutic man-
agement of active CMV infection in the allo-SCT
setting. In our cohort, the overall rate of CMV DNA-
emia was exceedingly high (almost 70%), which was
most likely related not only to the sensitivity of the
PCR assay employed for the surveillance of CMV
infection, but also to the high-risk profile of the study
group. In effect, almost 50% of patients received an
unrelated and/or HLA-mismatched graft, and 44%
of CMV-seropositive patients received a graft from
a CMV-seronegative donor. These pretransplant con-
ditions have been consistently associated with a high
incidence of active CMV infection in the allo-SCT
setting [2]. More than half of the initial episodes of
CMV DNAemia resolved spontaneously. The dura-
tion of self-resolving episodes of CMV DNAemia
was significantly shorter than that for episodes that
were eventually treated. Yet, these episodes lasted for
a median of 16 days. This finding should encourage
studies aimed at determining the impact of low-level
CMV replication, which is permitted when initiation
of antiviral treatment is delayed until a certain CMV
DNAemia threshold is reached (usually between 500
to 1000 CMV DNA copies/mL), on the incidence
and severity of indirect effects linked to CMV [1,2].
For most self-resolving episodes, the kinetics of
CMVplasmaDNA clearance did not follow a logarith-
mic decay curve; in fact, either fluctuating or rather
stable levels of CMV DNA loads were observed until
resolution. In agreement with data recently published
by Buyck et al. [12], the Kdecline for CMVDNA load in
episodes that resolved without antiviral therapy was
lower than that observed in episodes that required
antiviral treatment for resolution. Accordingly, the
half-life of CMV DNA load was shorter in the former
episodes. Notably, whole-blood samples were ana-
lyzed in the study by Buyck et al. [12], whereas plasma
specimens were used in the current study.
First, we asked whether the initial CMV plasma
DNA load value (first positive PCR result) may allow
for discrimination between episodes eventually requir-
ing antiviral therapy from those resolving without the
need of antiviral treatment. If this were the case, the
initiation of preemptive therapy could be anticipated,
perhaps leading to a more rapid resolution of the
episode and thereby minimizing the potential deleteri-
ous effects of continuous CMV replication. Even
though the median initial CMV DNA load was signif-
icantly lower for self-resolving episodes than for those
that required antiviral therapy for clearance, we found
a high degree of overlap among values measured in
both groups. It is known that the coefficient of varia-
tion of PCR assays for CMV DNA loads close to the
limit of detection, as were most of the initial values
in our patients, may be as high as 30% [19]. In light
of the above observations, the data suggested that
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ably predicting the subsequent kinetics of CMV
DNAemia is unlikely to be established, at least when
using highly sensitive real-time PCR assays, such as
the method employed in the current study, for moni-
toring of active CMV infection. In this sense, it must
be noted that initial CMV DNA loads measured in
this study were below the limit of detection of most
commercially available real-time PCRs [2].
We next sought to determine whether the compar-
ison between CMV DNA loads measured at baseline
(initial viral load) and shortly thereafter (second posi-
tive PCR—a median of 6 days after the first positive
PCR result)—would allow for identification of
episodes eventually requiring antiviral treatment. We
found significant increases of CMV DNA load
($3-fold) in 76% of episodes eventually requiring
antiviral treatment, but in \10% of self-resolving
episodes. The use of the above criterion would have
identified the episodes that eventually required anti-
viral treatment with a high sensitivity, specificity, and
positive and negative predictive values. In our cohort,
this strategy would have allowed for the anticipation
of the initiation of antiviral treatment in only 2 epi-
sodes (3 and 7 days), because the second CMV DNA-
emia value measured was above the established cutoff
for initiation of antiviral therapy; nevertheless, a larger
number of patients (6 of 13) would have benefited from
this strategy had a higher CMV DNAemia level
(1000 copies/mL) been set as the threshold for the ini-
tiation of antiviral therapy, as in other transplant cen-
ters. In light of these findings, studies designed to
determine whether anticipation of preemptive therapy
based on the above criterion would lead to a reduction
in the cumulative dose of antivirals administered or to
any clinically significant benefit are warranted. Prior
studies have proposed CMV plasma DNA level
increases of 174 copies/mL/day [5] or 266 copies be-
tween 2 consecutive determinations drawn a median
of 7 days apart [4] to discriminate between episodes
that required preemptive treatment and those that
did not. These estimations, nevertheless, were made
in the setting of a preemptive strategy consisting of
the initiation of antiviral therapy upon detection of
any level of pp65 antigenemia. In addition, Boeckh
and Ljungman [3] proposed an increase of $5-fold
for initiation of preemptive therapy in low-risk
allo-SCT recipients. To our knowledge, no data on
the clinical efficacy and safety of such strategies have
been published.
Preemptive antiviral therapy results in most cases
in a rapid decline of CMV DNA load (type A episodes
in the current study); nevertheless, increasing levels of
CMV DNAemia early after the initiation of antiviral
therapy (type B episodes in this study) are occasionally
documented [20-23]. This paradoxical phenomenon
has been related to a lack of prompt expansion offunctional CMV-specific T cells in response to viral
replication [23]. The occurrence of episodes with
a delayed response to antiviral therapy is associated
with an increased risk of CMV end-organ disease
[12]. Thus, early recognition of this type of episode
would allow for rapid therapeutic intervention,
perhaps including the use of adoptive immunotherapy,
in order to reduce the risk of CMV-related morbidity.
In this context, Buyck et al. [12] found a significantly
higher mean growth rate and higher baseline viral
load at the initiation of therapy in episodes with
a delayed response to therapy with respect to those
with an immediate response to therapy, whereas the
initial CMV DNA load appeared to be comparable
for both type of episodes. Our data partly agree with
those of Buyck et al. [12]. In effect, the CMV doubling
time was lower in type B than in type A episodes,
although statistical significance was not reached, and
the initial CMV DNA load did not differ significantly
between both types of episodes. Nevertheless, in con-
trast to the data reported in the above study, baseline
CMV DNA loads at the time of initiation of preemp-
tive therapy did not differ significantly between both
types of episodes. Thus, in our experience, the analysis
of the early kinetics ofCMVDNAemia did not allowus
to consistently identify the episodes of active CMV
infection with a delayed response to antiviral therapy.
Discrepancies between our data and those of Buyck
et al. [12] may be related to several factors, including
the use of different specimens for CMV DNA quanti-
fication, the use of distinct CMV DNA thresholds for
triggering the initiation of preemptive therapy and
the extensive use of Campath-1H in their study.
Recurrent episodes of active CMV infection
occurred with a comparable frequency among patients
who had an initial self-resolving episode and those who
developed an initial preemptively treated episode.
Nevertheless, the likelihood of experiencing a second-
ary episode that required antiviral therapy was higher
in patients who had developed a treated episode than
in those who had experienced a self-resolving episode.
In agreement with a previous study [12], the risk of
recurrence was not associated with the rate of CMV
DNA decline in primary treated episodes following
initiation of therapy. As for initial episodes, the base-
line CMV DNA load in secondary episodes did not
allow for a prediction of the subsequent kinetics of
CMV DNAemia. Nevertheless, in contrast to initial
episodes, variation in CMV DNA load between base-
line levels and those measured in the second positive
PCR did not allow for discrimination between epi-
sodes resolving spontaneously and those requiring
antiviral therapy. As ultimate control of CMV replica-
tion depends upon adequate expansion of functional
CMV-specific T cells [23,24], the above finding
likely reflected a more efficient and prompt T cell
response in secondary episodes.
1610 Biol Blood Marrow Transplant 17:1602-1611, 2011B. Mu~noz-Cobo et al.We were interested in assessing the impact of
several pretransplant and posttransplant clinical factors
on the kinetics ofCMVDNAemia during first episodes
of activeCMV infection, and the incidence of recurrent
episodes. Although we found no significant associa-
tions, a trend toward a higher frequency of episodes
that required antiviral therapy was observed in CMV
D2/R1 recipients, in patients who received umbilical
cord blood or HLA-mismatched grafts, in those who
received mycophenolate mofetil or prednisone
(\1 mg/kg/day) as a part of the GVHD prophylaxis
regimen and in patients who were treated with high
doses of corticosteroids (.1 mg/kg/day) for grades II
to IV GVHD. These findings were not unexpected as
all the above conditions have been shown to be associ-
ated with delayed CMV-specific immune recovery
[25-30]. In this context, it has previously been shown
that the magnitude and promptness of the expansion
of functional CMV-specific CD81 and CD41 T cells
in response to CMV replication critically determine
the kinetics of CMV DNAemia clearance [23]. Inter-
estingly, the use of rapamycin for the prevention of
GVHD was clearly associated with a relatively low
incidence of episodes that required antiviral treatment.
The scarce number of patients treated with this drug in
our cohort did not allow to draw definitive conclusions
on this issue; nevertheless, this effect has been previ-
ously documented in the solid organ transplantation
setting [31] and is likely because of a direct inhibitory
effect of rapamycin on viral replication [32].
Delayed recovery of CMV-specific T immunity
has been shown to be a significant risk factor for the
development of recurrent episodes of active CMV
infection in allo-SCT recipients [30,33]. In support
of this view, we found that CMV D2/R1 recipients
and patients who underwent unrelated/mismatched
or umbilical cord blood allo-SCT tended to experi-
ence recurrent episodes of active CMV infection
with higher frequencies. As mentioned above, all these
pretransplant and clinical conditions have been previ-
ously documented to be associated with an impairment
of CMV-specific T cell recovery.
The incidence of CMV end-organ disease in our
cohort was 3.3% (2 patients), which is in accordance
to data previously published by our group [4]. Unfor-
tunately, neither the analysis of the early kinetics of
CMV plasma DNAemia in the absence of antiviral
therapy nor the assessment of the dynamics of CMV
plasma DNA load following the instauration of anti-
viral treatment in these 2 episodes allowed for the an-
ticipation of the development of CMV end-organ
disease. Obviously, no definitive conclusions can be
drawn from these data given the limited number of
cases subjected to analysis.
This study has 2 main limitations. First, the
number of patients included in the cohort may have
been insufficient to assess precisely the impact ofpretransplant and clinical factors on the kinetics of
CMVDNAemia. Second, there might be certain inac-
curacies in the CMV DNAemia kinetics calculations
because of insufficient frequency of sampling. In this
respect, there is no consensus as to what should be
the frequency of CMV DNA load monitoring during
episodes of active CMV infection in the allo-SCT set-
ting; our data seemed to support the idea that the
schedule of once-a-week monitoring is probably safe,
as long as a highly sensitive PCR is used for the surveil-
lance of CMV infection. Nevertheless, it may also be
reasonable to implement the twice-a-week schedule
for high-risk patients, such as those receiving an unre-
lated or HLA-mismatched graft (including recipients
of umbilical cord blood transplants), in whom the dou-
bling time of CMV during the episodes of viral repli-
cation is clearly faster.
In summary, in the current study, we further char-
acterized the dynamics of CMV DNAemia during
initial and recurrent episodes of active CMV infection
in the allo-SCT setting. The data reported herein
should be taken into consideration for the design of
preemptive antiviral therapy strategies based on viro-
logic monitoring.ACKNOWLEDGMENTS
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